Published in J Immunol Res on April 09, 2014
Human Leucocyte Antigen G and Chronic Heart Failure | NCT03655925
Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 2.25
Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver? Cell Mol Immunol (2014) 0.90
Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. J Cell Mol Med (2015) 0.78
Evaluation of HLA-G 14 bp Ins/Del and +3142G>C Polymorphism with Susceptibility and Early Disease Activity in Rheumatoid Arthritis. Adv Med (2016) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2007) 3.49
Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet (2007) 2.58
A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med (1999) 2.36
Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A (2003) 2.33
Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood (2010) 2.15
The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens (2004) 2.13
Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol (2006) 2.08
Retracted Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol (2006) 2.00
Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A (2006) 1.78
Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol (2001) 1.69
Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood (2006) 1.65
KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol (2003) 1.60
A critical look at HLA-G. Trends Immunol (2008) 1.55
KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J Immunol (2002) 1.54
Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A (2002) 1.52
Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem (2006) 1.52
HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol (2001) 1.50
A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol (2007) 1.46
HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J (2005) 1.42
Trogocytosis-based generation of suppressive NK cells. EMBO J (2007) 1.40
HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics (2003) 1.38
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 1.36
Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6--STAT3 signaling pathway. Proc Natl Acad Sci U S A (2008) 1.32
Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol (2003) 1.23
The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol (2005) 1.21
Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci U S A (2005) 1.20
Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol (2007) 1.15
Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol (2003) 1.13
Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood (2006) 1.13
Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun (2004) 1.13
A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol Hum Reprod (2008) 1.12
Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol (2003) 1.12
CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood (2007) 1.11
Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens (1999) 1.11
Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation (2002) 1.10
HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol (1998) 1.10
Implication of HLA-G molecule in heart-graft acceptance. Lancet (2000) 1.09
HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics (2004) 1.09
Does 'soluble' HLA-G really exist? Another twist to the tale. Mol Hum Reprod (2005) 1.09
MiRNA-mediated control of HLA-G expression and function. PLoS One (2012) 1.08
The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci (2012) 1.08
HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology (2000) 1.07
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology (2007) 1.06
Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistological demonstration with anti-HLA-G specific antibody "87G" and anti-cytokeratin antibody "CAM5.2". Am J Reprod Immunol (1996) 1.06
Soluble HLA-G isoforms: technical deficiencies lead to misinterpretations. Mol Hum Reprod (2005) 1.05
A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem (2000) 1.05
Immunomodulatory molecules are released from the first trimester and term placenta via exosomes. Placenta (2012) 1.04
Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004. Hum Immunol (2005) 1.04
A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol (2011) 1.03
Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol (1999) 1.03
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics (2006) 1.02
HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens (2008) 1.01
Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol (1997) 1.00
HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia. Am J Obstet Gynecol (2004) 1.00
Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS (2004) 0.99
Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol (2003) 0.97
HLA-G5 expression by trophoblast cells: the facts. Mol Hum Reprod (2005) 0.97
Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol (2006) 0.97
In vivo identification of an HLA-G complex as ubiquitinated protein circulating in exosomes. Eur J Immunol (2013) 0.96
The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod (2006) 0.96
Detection of HLA-G5 secreting cells. Hum Immunol (2003) 0.96
Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS One (2010) 0.96
The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes (2006) 0.96
Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol (2006) 0.95
Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem (1994) 0.94
Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. Am J Reprod Immunol (2009) 0.94
HLA-G unique promoter region: functional implications. Immunogenetics (2001) 0.94
Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens (2011) 0.94
Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol (2006) 0.93
Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. Hum Immunol (2006) 0.92
A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc (2001) 0.92
Detection of HLA-G by a specific sandwich ELISA using monoclonal antibodies G233 and 56B. Mol Hum Reprod (2002) 0.92
Soluble HLA-G and control of angiogenesis. J Reprod Immunol (2007) 0.91
Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol (2003) 0.91
HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol (1999) 0.91
Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol (2004) 0.90
Modulation of HLA-G antigens expression in myelomonocytic cells. Hum Immunol (2000) 0.90
HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum Immunol (2012) 0.89
The expression and functional activity of membrane-bound human leukocyte antigen-G1 are influenced by the 3'-untranslated region. Hum Immunol (2013) 0.89
Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. Clin Exp Immunol (2007) 0.89
Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transpl Immunol (2007) 0.89
HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol (2012) 0.89
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem (2013) 0.88
Soluble HLA-G expression and renal graft acceptance. Am J Transplant (2006) 0.88
Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod (2006) 0.88
Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab (2000) 0.88
Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J Reprod Immunol (1999) 0.87
Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci (2006) 0.87
Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones (2000) 0.87
Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: longitudinal study during pregnancy. Hum Immunol (2007) 0.86
Production of sHLA-G molecules by in vitro matured cumulus-oocyte complex. Int J Mol Med (2009) 0.85
Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci (2011) 0.85
Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell Mol Life Sci (2012) 0.85
Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol (2007) 0.85
Quantification and identification of soluble HLA-G isoforms. Tissue Antigens (2007) 0.84
Human immunodeficiency virus 1 downregulates cell surface expression of the non-classical major histocompatibility class I molecule HLA-G1. J Gen Virol (2004) 0.83
Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens (2000) 0.83
Focus on the importance of soluble human leukocyte antigen G as a marker for embryo selection in assisted reproductive technology. Fertil Steril (2013) 1.08
In vivo identification of an HLA-G complex as ubiquitinated protein circulating in exosomes. Eur J Immunol (2013) 0.96
Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: longitudinal study during pregnancy. Hum Immunol (2007) 0.86
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Mult Scler (2015) 0.82
Membrane redistributions through multi-intercellular exchanges and serial trogocytosis. Cell Res (2010) 0.80
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment. Dis Markers (2015) 0.79
Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases. J Immunol Res (2016) 0.77
Pseudomonas aeruginosa Quorum Sensing Molecule N-(3-Oxododecanoyl)-L-Homoserine-Lactone Induces HLA-G Expression in Human Immune Cells. Infect Immun (2015) 0.76
Study of Soluble HLA-G in Congenital Human Cytomegalovirus Infection. J Immunol Res (2016) 0.75
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients. Dis Markers (2016) 0.75
Correction for Bortolotti et al., "Pseudomonas aeruginosa Quorum Sensing Molecule N-(3-Oxododecanoyl)-l-Homoserine-Lactone Induces HLA-G Expression in Human Immune Cells". Infect Immun (2017) 0.75
The role of HLA-class Ib molecules in immune-related diseases, tumors, and infections. J Immunol Res (2014) 0.75
The Role of HLA-Class Ib Molecules in Immune-Related Diseases, Tumors, and Infections 2016. J Immunol Res (2017) 0.75
SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. Cells (2020) 0.75